Pharmacological modulation of glutamate has long been considered to be of immense
therapeutic utility. The metabotropic glutamate receptors (mGluRs) are potential targets for …

The investigation of novel drug targets for treating cognitive impairments associated with
neurological and psychiatric disorders remains a primary focus of study in central nervous …

Current treatments for depression are less than optimal in terms of onset of action, response
and remission rates, and side-effect profiles. Glutamate is the major excitatory …

Major depressive disorder is among the most prevalent forms of mental illness. All currently
available antidepressant medications have stemmed from study of the mechanisms of …

Cognitive impairment, in particular of attention and memory, is often reported by patients
suffering from major depressive disorder (MDD) and deficits in attention are part of the …

Introduction: The trace amines, endogenous amines closely related to the biogenic amine
neurotransmitters, have been known to exert physiological and neurological effects for …

Advanced leads from a series of 1, 2, 4-triazolo [4, 3-a] pyridines with mGlu2 receptor PAM
activity are reported. By modification of the analogous imidazo [1, 2-a] pyridine series, the …

Unlike conventional drug substances, herbal medicines are composed of a complex of
biologically active compounds. Therefore, the potential occurrence of herb-drug interactions …

Sleep and/or circadian rhythm disruption (SCRD) is seen in up to 80% of schizophrenia
patients. The co-morbidity of schizophrenia and SCRD may in part stem from dysfunction in …

Compiling pharmacological evidence implicates metabotropic glutamate mGlu2 receptors in
the regulation of emotional states and suggests positive modulators as a novel therapeutic …